Last reviewed · How we verify
ZIAGEN®
ZIAGEN (abacavir) is a nucleoside reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating.
ZIAGEN (abacavir) is a nucleoside reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating. Used for HIV-1 infection (in combination with other antiretroviral agents).
At a glance
| Generic name | ZIAGEN® |
|---|---|
| Also known as | abacavir sulfate |
| Sponsor | ViiV Healthcare |
| Drug class | Nucleoside reverse transcriptase inhibitor (NRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Abacavir is a guanosine analog that gets phosphorylated intracellularly and incorporated into the growing HIV DNA chain during reverse transcription, causing chain termination. By inhibiting reverse transcriptase, it prevents HIV from integrating into the host cell genome and establishing productive infection. It is typically used as part of combination antiretroviral therapy (cART) to suppress viral replication.
Approved indications
- HIV-1 infection (in combination with other antiretroviral agents)
Common side effects
- Hypersensitivity reaction
- Nausea
- Headache
- Diarrhea
- Fatigue
- Insomnia
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study of GS-3242 in Participants With HIV-1; Substudy-05 (PHASE1)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study of GS-1219 in Participants With HIV-1 (PHASE1)
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (PHASE4)
- A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZIAGEN® CI brief — competitive landscape report
- ZIAGEN® updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI